FGFR2 Gene Mutation clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with Fibroblast Growth Factor receptor (FGFR) genetic alterations.
at UCLA UCSF